These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 34714360)

  • 1. Pharmacological chaperones improve intra-domain stability and inter-domain assembly via distinct binding sites to rescue misfolded CFTR.
    Baatallah N; Elbahnsi A; Mornon JP; Chevalier B; Pranke I; Servel N; Zelli R; Décout JL; Edelman A; Sermet-Gaudelus I; Callebaut I; Hinzpeter A
    Cell Mol Life Sci; 2021 Dec; 78(23):7813-7829. PubMed ID: 34714360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1.
    Ren HY; Grove DE; De La Rosa O; Houck SA; Sopha P; Van Goor F; Hoffman BJ; Cyr DM
    Mol Biol Cell; 2013 Oct; 24(19):3016-24. PubMed ID: 23924900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination.
    Veit G; Roldan A; Hancock MA; Da Fonte DF; Xu H; Hussein M; Frenkiel S; Matouk E; Velkov T; Lukacs GL
    JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32853178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment.
    Capurro V; Tomati V; Sondo E; Renda M; Borrelli A; Pastorino C; Guidone D; Venturini A; Giraudo A; Mandrup Bertozzi S; Musante I; Bertozzi F; Bandiera T; Zara F; Galietta LJV; Pedemonte N
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34067708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism-based corrector combination restores ΔF508-CFTR folding and function.
    Okiyoneda T; Veit G; Dekkers JF; Bagdany M; Soya N; Xu H; Roldan A; Verkman AS; Kurth M; Simon A; Hegedus T; Beekman JM; Lukacs GL
    Nat Chem Biol; 2013 Jul; 9(7):444-54. PubMed ID: 23666117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correctors of the Major Cystic Fibrosis Mutant Interact through Membrane-Spanning Domains.
    Laselva O; Molinski S; Casavola V; Bear CE
    Mol Pharmacol; 2018 Jun; 93(6):612-618. PubMed ID: 29618585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergy-based small-molecule screen using a human lung epithelial cell line yields ΔF508-CFTR correctors that augment VX-809 maximal efficacy.
    Phuan PW; Veit G; Tan J; Roldan A; Finkbeiner WE; Lukacs GL; Verkman AS
    Mol Pharmacol; 2014 Jul; 86(1):42-51. PubMed ID: 24737137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational Exploration of Potential CFTR Binding Sites for Type I Corrector Drugs.
    Lester A; Sandman M; Herring C; Girard C; Dixon B; Ramsdell H; Reber C; Poulos J; Mitchell A; Spinney A; Henager ME; Evans CN; Turlington M; Johnson QR
    Biochemistry; 2023 Aug; 62(16):2503-2515. PubMed ID: 37437308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Analysis of Combinatorial Pharmacological Treatments to Correct Nonsense Mutations in the CFTR Gene.
    Venturini A; Borrelli A; Musante I; Scudieri P; Capurro V; Renda M; Pedemonte N; Galietta LJV
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PTI-801 (posenacaftor) shares a common mechanism with VX-445 (elexacaftor) to rescue p.Phe508del-CFTR.
    Ferreira FC; Amaral MD; Bacalhau M; Lopes-Pacheco M
    Eur J Pharmacol; 2024 Mar; 967():176390. PubMed ID: 38336013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
    N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The investigational Cystic Fibrosis drug Trimethylangelicin directly modulates CFTR by stabilizing the first membrane-spanning domain.
    Laselva O; Molinski S; Casavola V; Bear CE
    Biochem Pharmacol; 2016 Nov; 119():85-92. PubMed ID: 27614011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR.
    Lopes-Pacheco M; Silva IAL; Turner MJ; Carlile GW; Sondo E; Thomas DY; Pedemonte N; Hanrahan JW; Amaral MD
    Biochem Pharmacol; 2020 Oct; 180():114133. PubMed ID: 32628927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis.
    Brandas C; Ludovico A; Parodi A; Moran O; Millo E; Cichero E; Baroni D
    Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive mapping of cystic fibrosis mutations to CFTR protein identifies mutation clusters and molecular docking predicts corrector binding site.
    Molinski SV; Shahani VM; Subramanian AS; MacKinnon SS; Woollard G; Laforet M; Laselva O; Morayniss LD; Bear CE; Windemuth A
    Proteins; 2018 Aug; 86(8):833-843. PubMed ID: 29569753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CFTR modulator therapy for cystic fibrosis caused by the rare c.3700A>G mutation.
    Phuan PW; Haggie PM; Tan JA; Rivera AA; Finkbeiner WE; Nielson DW; Thomas MM; Janahi IA; Verkman AS
    J Cyst Fibros; 2021 May; 20(3):452-459. PubMed ID: 32674984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Revertants, low temperature, and correctors reveal the mechanism of F508del-CFTR rescue by VX-809 and suggest multiple agents for full correction.
    Farinha CM; King-Underwood J; Sousa M; Correia AR; Henriques BJ; Roxo-Rosa M; Da Paula AC; Williams J; Hirst S; Gomes CM; Amaral MD
    Chem Biol; 2013 Jul; 20(7):943-55. PubMed ID: 23890012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corrector VX-809 stabilizes the first transmembrane domain of CFTR.
    Loo TW; Bartlett MC; Clarke DM
    Biochem Pharmacol; 2013 Sep; 86(5):612-9. PubMed ID: 23835419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel tricyclic pyrrolo-quinolines as pharmacological correctors of the mutant CFTR chloride channel.
    Renda M; Barreca M; Borrelli A; Spanò V; Montalbano A; Raimondi MV; Bivacqua R; Musante I; Scudieri P; Guidone D; Buccirossi M; Genovese M; Venturini A; Bandiera T; Barraja P; Galietta LJV
    Sci Rep; 2023 May; 13(1):7604. PubMed ID: 37165082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
    Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
    N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.